SFRP4 and prostate carcinoma: Protein levels of SFRP4 measured by immunohistochemistry is discordant in prostate cancer; Horvath et al. 13,14 reported increased expression of membranous SFRP4 staining to be associated with good prognosis, while Mortensen et al. 10 reported cytoplasmic expression to be linked to worse prognosis.